药物玻璃体溶解术的研究进展  

Progression of pharmacologic vitreolysis research

作　　者：周慧颖[1] 叶俊杰[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院眼科, 100730

出　　处：《中华眼科杂志》2014年第3期225-229,共5页Chinese Journal of Ophthalmology

摘　　要：近年来,人们认识到玻璃体与视网膜粘连可引发多种眼底病变.以往我们使用玻璃体切除术解除玻璃体与视网膜的粘连,但玻璃体切除术时会遇到玻璃体与视网膜粘连分离不完全、玻璃体残留和手术并发症的限制.然而,药物玻璃体溶解术给我们提供了治疗持续病理性玻璃体黄斑粘连的另一个治疗途径.本文对玻璃体分子组织结构、玻璃体后脱离的基本原理,以及当前药物玻璃体溶解术的研究进展进行综述.It is now well recognized that vitreomacular adhesion （VMA） plays an important role in the pathogenesis of various retinopathy.Traction released through pars plana vitrectomy was used before,but it is limited by some problems such as incomplete vitreoretinal separation,vitreous remnant and other operative complications.While another new method-Pharmacologic Vitreolysis provided us a new method for persistent pathologic VMA treatment.This review aims to introduce the vitreous molecular structure,principles of posterior vitreous detachment and progression of pharmacologic vitreolysis method study.

关 键 词：玻璃体内注射 纤溶酶 透明质酸葡糖胺酶 玻璃体脱离 视网膜疾病 

分 类 号：R776.4[医药卫生—眼科]